Maze Therapeutics, Inc.
MAZE
$41.49
$4.2211.32%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 10.67% | -2.72% | -10.84% | -19.50% | -117.80% |
| Total Depreciation and Amortization | -12.02% | -5.12% | -2.98% | -10.53% | -7.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.89% | 0.12% | -25.60% | -10.02% | 121.15% |
| Change in Net Operating Assets | 148.27% | 27.16% | -238.22% | 119.71% | -315.40% |
| Cash from Operations | 18.00% | -1.82% | -31.46% | 3.24% | -116.00% |
| Capital Expenditure | 82.70% | -31.44% | 50.58% | -487.38% | 35.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -16,918.58% | -31.44% | 50.58% | -487.38% | 35.63% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 23,389.71% | -99.52% | 202,880.95% | -72.12% | 186.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 15.82% | 75.00% | -1,191.30% |
| Cash from Financing | 23,389.71% | -99.52% | 81.29% | 3,368.00% | -1,496.10% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 275.08% | -130.58% | 106.68% | 285.42% | -117.55% |